Oral dabigatran etexilate versus enoxaparin for venous thromboembolism prevention after total hip arthroplasty: pooled analysis of two phase 3 randomized trials

BACKGROUND: Two phase 3 trials compared 28–35 days of treatment with oral dabigatran 220 mg or 150 mg (RE-NOVATE) or 220 mg (RE-NOVATE II) once daily with subcutaneous enoxaparin 40 mg once daily for prevention of venous thromboembolism (VTE) after elective total hip arthroplasty. METHODS: This pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksson, Bengt I., Dahl, Ola E., Rosencher, Nadia, Clemens, Andreas, Hantel, Stefan, Feuring, Martin, Kreuzer, Jörg, Huo, Michael, Friedman, Richard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Original Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647514/
https://www.ncbi.nlm.nih.gov/pubmed/26578849
http://dx.doi.org/10.1186/s12959-015-0067-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647514/
https://www.ncbi.nlm.nih.gov/pubmed/26578849
http://dx.doi.org/10.1186/s12959-015-0067-8

Ejemplares similares